127 related articles for article (PubMed ID: 37999452)
21. Cost-effectiveness analysis of dasatinib versus imatinib in pediatric philadelphia chromosome-positive acute lymphoblastic leukemia patients in China.
Cao W; Yu Y; Qiu Y; Liu L; Zhang H; Shi L; Xiao Y; Jia L; Zhang R; Wang X
BMC Health Serv Res; 2022 Dec; 22(1):1580. PubMed ID: 36567324
[TBL] [Abstract][Full Text] [Related]
22. Indirect comparisons of efficacy of zanubrutinib versus orelabrutinib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma or relapsed or refractory mantle cell lymphoma.
Song Y; Zhou K; Yang S; Hu J; Zou D; Gao S; Pan L; Wang T; Yang H; Zhang H; Zhou D; Ji J; Xu W; Feng R; Jin J; Lv F; Huang H; Fan X; Xu S; Zhu J
Invest New Drugs; 2023 Aug; 41(4):606-616. PubMed ID: 37420136
[TBL] [Abstract][Full Text] [Related]
23. Degarelix vs. leuprorelin for the treatment of prostate cancer in China: A cost-utility analysis.
Yan J; Li C; Zhang X; Cheng L; Ding R; Zhang L
Front Public Health; 2022; 10():942800. PubMed ID: 35923949
[TBL] [Abstract][Full Text] [Related]
24. Cost-Effectiveness Model for Chemoimmunotherapy Options in Patients with Previously Untreated Chronic Lymphocytic Leukemia Unsuitable for Full-Dose Fludarabine-Based Therapy.
Becker U; Briggs AH; Moreno SG; Ray JA; Ngo P; Samanta K
Value Health; 2016 Jun; 19(4):374-82. PubMed ID: 27325329
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness and budget impact of venetoclax in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia in Switzerland.
Barbier M; Durno N; Bennison C; Örtli M; Knapp C; Schwenkglenks M
Eur J Health Econ; 2022 Jul; 23(5):837-846. PubMed ID: 34757508
[TBL] [Abstract][Full Text] [Related]
26. Active Tuberculosis Screening via a Mobile Health App in Myanmar: Incremental Cost-Effectiveness Evaluation.
Htet KKK; Phyu AN; Zayar NN; Chongsuvivatwong V
JMIR Form Res; 2023 Nov; 7():e51998. PubMed ID: 37948119
[TBL] [Abstract][Full Text] [Related]
27. Ibrutinib for Treating Relapsed or Refractory Mantle Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Tappenden P; Simpson E; Hamilton J; Pollard D; Clowes M; Kaltenthaler E; Meiklejohn D; Morley N
Pharmacoeconomics; 2019 Mar; 37(3):333-343. PubMed ID: 30246228
[TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness of a 12-month fixed-duration venetoclax treatment in combination with obinutuzumab in first-line, unfit chronic lymphocytic leukemia in the United States.
Chatterjee A; Shapouri S; Manzoor BS; Ravelo A; Sail K; Qendri V; van de Wetering G; Davids MS
J Manag Care Spec Pharm; 2021 Nov; 27(11):1532-1544. PubMed ID: 34714110
[No Abstract] [Full Text] [Related]
29. Cost-Effectiveness Analysis of Rituximab for Chronic Lymphocytic Leukemia Using a Semi-Markovian Model Approach in R.
Santos AS; Andrade JP; Freitas DA; Gonçalves ÉSD; Borges DL; Carvalho LMA; Noronha KVMS; Andrade MV
Value Health Reg Issues; 2023 Jul; 36():10-17. PubMed ID: 36966699
[TBL] [Abstract][Full Text] [Related]
30. Cost-Effectiveness Analysis of Relmacabtagene Autoleucel for Relapsed or Refractory Large B-Cell Lymphoma in China.
Lin Z; Zuo C; Jiang Y; Su W; Yao X; Man Y; Wu Q; Xuan J
Value Health Reg Issues; 2023 Sep; 37():41-48. PubMed ID: 37209540
[TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness of Maintenance Capecitabine and Bevacizumab for Metastatic Colorectal Cancer.
Sherman SK; Lange JJ; Dahdaleh FS; Rajeev R; Gamblin TC; Polite BN; Turaga KK
JAMA Oncol; 2019 Feb; 5(2):236-242. PubMed ID: 30489611
[TBL] [Abstract][Full Text] [Related]
32. Economic Evaluation of Sevelamer versus Calcium-based Binders in Treating Hyperphosphatemia among Patients with End-stage Renal Disease in China.
Yang L; Chuen Tan S; Chen C; Wang X; Li X; Yang X
Clin Ther; 2016 Nov; 38(11):2459-2467.e1. PubMed ID: 27751671
[TBL] [Abstract][Full Text] [Related]
33. Phase I/II Clinical Trial-Based Early Economic Evaluation of Acalabrutinib for Relapsed Chronic Lymphocytic Leukaemia.
Vreman RA; Geenen JW; Hövels AM; Goettsch WG; Leufkens HGM; Al MJ
Appl Health Econ Health Policy; 2019 Dec; 17(6):883-893. PubMed ID: 31317510
[TBL] [Abstract][Full Text] [Related]
34. Using Genomic Information to Guide Ibrutinib Treatment Decisions in Chronic Lymphocytic Leukaemia: A Cost-Effectiveness Analysis.
Buchanan J; Wordsworth S; Clifford R; Robbe P; Taylor JC; Schuh A; Knight SJL
Pharmacoeconomics; 2017 Aug; 35(8):845-858. PubMed ID: 28762015
[TBL] [Abstract][Full Text] [Related]
35. Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study.
Shadman M; Flinn IW; Levy MY; Porter RF; Burke JM; Zafar SF; Misleh J; Kingsley EC; Yimer HA; Freeman B; Rao SS; Chaudhry A; Tumula PK; Gandhi MD; Manda S; Chen DY; By K; Xu L; Liu Y; Crescenzo R; Idoine A; Zhang X; Cohen A; Huang J; Sharman JP
Lancet Haematol; 2023 Jan; 10(1):e35-e45. PubMed ID: 36400069
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness analysis of tenofovir disoproxil fumarate for treatment of chronic hepatitis B in China.
Ke W; Zhang C; Liu L; Gao Y; Yao Z; Ye X; Zhou S; Yang Y
Hepatol Int; 2016 Nov; 10(6):924-936. PubMed ID: 27271357
[TBL] [Abstract][Full Text] [Related]
37. Endovascular treatment for basilar artery occlusion: a cost-effectiveness analysis based on a meta-analysis.
Wang L; Yu Y; Zhou L; Xu P; Guo X; Xie Y; Cai J; Pan M; Tang J; Gong Q; Su R; Lou Y; Liu Y
Front Neurol; 2023; 14():1267554. PubMed ID: 37928158
[TBL] [Abstract][Full Text] [Related]
38. Zanubrutinib for the treatment of lymphoid malignancies: Current status and future directions.
Wolska-Washer A; Robak T
Front Oncol; 2023; 13():1130595. PubMed ID: 37035197
[TBL] [Abstract][Full Text] [Related]
39. Immunosuppressive therapy for progressive idiopathic membranous nephropathy: a cost-effectiveness analysis in China.
Xu W; Zhang Z; Li D; Dai W; Pan C; Guo M; Zhao Y; Cui X
BMC Health Serv Res; 2023 Apr; 23(1):361. PubMed ID: 37046255
[TBL] [Abstract][Full Text] [Related]
40. Long-term Survival and Value of Chimeric Antigen Receptor T-Cell Therapy for Pediatric Patients With Relapsed or Refractory Leukemia.
Whittington MD; McQueen RB; Ollendorf DA; Kumar VM; Chapman RH; Tice JA; Pearson SD; Campbell JD
JAMA Pediatr; 2018 Dec; 172(12):1161-1168. PubMed ID: 30304407
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
